Fiber Fermentation Study
Not Applicable
Completed
- Conditions
- Intestinal Health
- Registration Number
- NCT04570137
- Lead Sponsor
- University of Hohenheim
- Brief Summary
The aim of the study is to better understand the interplay between the intake of dietary fiber and intestinal bacteria, their metabolic activity and the effect on the intestinal barrier.
The effect of two different dietary fiber supplements is tested (arabinoxylan \& ß-glucan versus inulin \& fructooligosaccharides) in a randomized crossover intervention trial including healthy volunteers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
- 18 to 65 years
- signed written informed consent
- willingness not to change the dietary pattern in the course of the study
Exclusion Criteria
- BMI below 18 or above 30
- acute or chronic gastrointestinal symptoms
- neoplastic diseases
- very strict diets, including raw foodists and frutarians
- regular smoking (more than one box per day)
- intake of antibiotics, immunosuppressants, or any intestinal therapeutics three months prior to study begin
- supplementation of fibers three months prior to study begin
- simultaneous participation in another clinical study
- pregnancy / breastfeeding
- relevant violations of the study protocol
- intolerance to the fiber supplements (including wheat, oat, chicory)
- occurrence of relevant diseases (individual decision by study physicians)
- revocation of consent
- placement in a clinic or similar facility based on an official or court order
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Short-chain fatty acids (SCFAs) Will be measured in approx. 4 weeks after study completion. SCFAs in native fecal samples
- Secondary Outcome Measures
Name Time Method Gut microbiome composition Will be measured in approx. 6-8 weeks after study completion. 16S NGS sequencing
Gut barrier integrity Will be measured in approx. 4 weeks after study completion. Lipopolysaccharide-binding protein (plasma) and zonulin (feces)
Trial Locations
- Locations (1)
Institute of Nutritional Medicine, University of Hohenheim
🇩🇪Stuttgart, Germany
Institute of Nutritional Medicine, University of Hohenheim🇩🇪Stuttgart, Germany